PUBLISHER: Allied Market Research | PRODUCT CODE: 1472248

PUBLISHER: Allied Market Research | PRODUCT CODE: 1472248

Comprehensive Metabolic Panel Testing Market By Test Type, By Disease Indication, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

PUBLISHED: February 1, 2024

PAGES: 266 Pages

DELIVERY TIME: 2-3 business days

SELECT AN OPTION

The comprehensive metabolic panel testing market was valued at $10.1 billion in 2022 and is projected to reach $16.1 billion by 2032, registering a CAGR of 4.8% from 2023 to 2032. The comprehensive metabolic panel (CMP) is a blood test that measures several substances in the blood. The comprehensive metabolic panel test measures glucose levels, which indicates the level of sugar in the blood and is used to diagnose diabetes or monitor existing cases. In addition, CMP tests include testing of electrolytes such as sodium, potassium and chloride, which are crucial in maintaining fluid balance and carrying out proper nerve and muscle function such as contractility.

Comprehensive Metabolic Panel Testing Market - IMG1

Furthermore, CMP studies kidney operations through determination of varying amounts of urea nitrogen (BUN) and creatinine in individual's blood contributes early detection of renal problems which drives the demand for CMP testing and supports market growth. For instance, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), both examine liver health by indicating damage or illness occurrence within it. Overall, a comprehensive metabolic panel provides a comprehensive overview of key physiological processes, aiding healthcare professionals in diagnosing and managing various medical conditions.

Factors driving the growth of the comprehensive metabolic panel testing market include increased demand for diagnostic services and chronic conditions such as diabetes, cardiovascular diseases, and stroke that require accurate equipment timely diagnostic tools such as CMP testing essential. For instance, according to the Centers for Disease Control and Prevention (CDC), by 2022, 6 out of 10 adults in the U.S. had diabetes. Thus, the rise in prevalence of conditions such as diabetes, cardiovascular diseases, and kidney diseases requires regular biopsies, which drives the growth of the market.

In addition, rise in health care awareness and screening programs contribute significantly to the need for comprehensive metabolic panel (CMP) test. As preventive healthcare becomes more important in public health initiatives, they have become key components in educating people on the benefits of routine check-ups. These schemes promote early recognition and intervention, thus cultivating proactive management practices regarding healthcare, which fuels market growth. Furthermore, the shift toward preventive healthcare is a key factor driving the comprehensive metabolic panel testing market growth. As healthcare evolves, with a surge in emphasis on prompt healthcare and early diagnosis, this trend encourages individuals to adopt regular health screenings, prioritizing the identification of potential health risks before they manifest in more severe situations, thereby driving market growth.

Moreover, the growing elderly population demands the need for health care and diagnostic testing. Older individuals often require more frequent health check-ups with a comprehensive metabolic program to monitor their overall health and manage chronic conditions as older people are more likely to develop chronic conditions such as diabetes, heart disease and kidney disease. Comprehensive histology, which provides comprehensive biochemical information, is important in maintaining the health of older people and managing these conditions.

However, a lack of awareness among both individuals and healthcare providers poses a significant obstacle to the expansion of the comprehensive metabolic panel testing sector. In addition, stringent regulatory requirements and compliance standards in the healthcare business provide difficulties for laboratories and diagnostic service providers thereby hampering market growth. In contrast, the expansion of point-of-care testing allows for rapid on-site results, providing convenience and quick decision-making for healthcare professionals. Developing and adopting CMP testing as part of point-of-care solutions, particularly in decentralized healthcare settings, provides lucrative opportunity for market growth.

The comprehensive metabolic panel testing market is segmented on the basis of test type, disease indication, end user, and region. By test type, the market is classified into proteins, electrolytes, kidney tests, liver test, and others. By disease indication the market is categorized into kidney diseases, liver diseases, diabetes, and others. By end user, it is segregated into hospitals, diagnostic laboratories, and others.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA). Major key players that operate in the comprehensive metabolic panel testing market are Quest Diagnostics, Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Blueprint Genetics, ARUP Laboratories, Walk-In Lab, LLC., Applied InGENuity Diagnostics, Scion Lab Services, LLC, Baptist Health, and My Care Labs. Key players have adopted acquisition, product approval and product launch as key developmental strategies to improve the product portfolio of the comprehensive metabolic panel testing market.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the comprehensive metabolic panel testing market analysis from 2022 to 2032 to identify the prevailing comprehensive metabolic panel testing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the comprehensive metabolic panel testing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global comprehensive metabolic panel testing market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Criss-cross segment analysis- market size and forecast
Expanded list for Company Profiles
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Test Type

Proteins
Electrolytes
Kidney Tests
Liver Tests
Others

By Disease Indication

Kidney Diseases
Liver Diseases
Diabtes
Others

By End User

Hospitals
Diagnostic Laboratories
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Colombia
- Argentina
- Rest Of La
Middle East and Africa
- Gcc
- South Africa
- North Africa
- Rest Of Mea

Key Market Players:

Quest Diagnostics
Laboratory Corporation of America Holdings
F. Hoffmann-La Roche Ltd.
ARUP Laboratories
Walk-In Lab, LLC.
Applied InGENuity Diagnostics
Scion Lab Services, LLC
Baptist Health
My Care Labs
Blueprint Genetics

Product Code: A269963

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Proteins
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Electrolytes
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Kidney Tests
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Liver Tests
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
4.6. Others
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country

CHAPTER 5: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Kidney Diseases
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Liver Diseases
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Diabetes
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Others
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country

CHAPTER 6: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Diagnostic Laboratories
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Others
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Test Type
- 7.2.3. Market size and forecast, by Disease Indication
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Test Type
  - 7.2.5.1.2. Market size and forecast, by Disease Indication
  - 7.2.5.1.3. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Test Type
  - 7.2.5.2.2. Market size and forecast, by Disease Indication
  - 7.2.5.2.3. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Test Type
  - 7.2.5.3.2. Market size and forecast, by Disease Indication
  - 7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Test Type
- 7.3.3. Market size and forecast, by Disease Indication
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Test Type
  - 7.3.5.1.2. Market size and forecast, by Disease Indication
  - 7.3.5.1.3. Market size and forecast, by End User
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Test Type
  - 7.3.5.2.2. Market size and forecast, by Disease Indication
  - 7.3.5.2.3. Market size and forecast, by End User
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Test Type
  - 7.3.5.3.2. Market size and forecast, by Disease Indication
  - 7.3.5.3.3. Market size and forecast, by End User
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Test Type
  - 7.3.5.4.2. Market size and forecast, by Disease Indication
  - 7.3.5.4.3. Market size and forecast, by End User
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Test Type
  - 7.3.5.5.2. Market size and forecast, by Disease Indication
  - 7.3.5.5.3. Market size and forecast, by End User
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Test Type
  - 7.3.5.6.2. Market size and forecast, by Disease Indication
  - 7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Test Type
- 7.4.3. Market size and forecast, by Disease Indication
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Test Type
  - 7.4.5.1.2. Market size and forecast, by Disease Indication
  - 7.4.5.1.3. Market size and forecast, by End User
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Test Type
  - 7.4.5.2.2. Market size and forecast, by Disease Indication
  - 7.4.5.2.3. Market size and forecast, by End User
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Test Type
  - 7.4.5.3.2. Market size and forecast, by Disease Indication
  - 7.4.5.3.3. Market size and forecast, by End User
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Test Type
  - 7.4.5.4.2. Market size and forecast, by Disease Indication
  - 7.4.5.4.3. Market size and forecast, by End User
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Test Type
  - 7.4.5.5.2. Market size and forecast, by Disease Indication
  - 7.4.5.5.3. Market size and forecast, by End User
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Test Type
  - 7.4.5.6.2. Market size and forecast, by Disease Indication
  - 7.4.5.6.3. Market size and forecast, by End User
7.5. Latin America
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Test Type
- 7.5.3. Market size and forecast, by Disease Indication
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Test Type
  - 7.5.5.1.2. Market size and forecast, by Disease Indication
  - 7.5.5.1.3. Market size and forecast, by End User
  - 7.5.5.2. Colombia
  - 7.5.5.2.1. Market size and forecast, by Test Type
  - 7.5.5.2.2. Market size and forecast, by Disease Indication
  - 7.5.5.2.3. Market size and forecast, by End User
  - 7.5.5.3. Argentina
  - 7.5.5.3.1. Market size and forecast, by Test Type
  - 7.5.5.3.2. Market size and forecast, by Disease Indication
  - 7.5.5.3.3. Market size and forecast, by End User
  - 7.5.5.4. Rest Of La
  - 7.5.5.4.1. Market size and forecast, by Test Type
  - 7.5.5.4.2. Market size and forecast, by Disease Indication
  - 7.5.5.4.3. Market size and forecast, by End User
7.6. Middle East and Africa
- 7.6.1. Key market trends, growth factors and opportunities
- 7.6.2. Market size and forecast, by Test Type
- 7.6.3. Market size and forecast, by Disease Indication
- 7.6.4. Market size and forecast, by End User
- 7.6.5. Market size and forecast, by country
  - 7.6.5.1. Gcc
  - 7.6.5.1.1. Market size and forecast, by Test Type
  - 7.6.5.1.2. Market size and forecast, by Disease Indication
  - 7.6.5.1.3. Market size and forecast, by End User
  - 7.6.5.2. South Africa
  - 7.6.5.2.1. Market size and forecast, by Test Type
  - 7.6.5.2.2. Market size and forecast, by Disease Indication
  - 7.6.5.2.3. Market size and forecast, by End User
  - 7.6.5.3. North Africa
  - 7.6.5.3.1. Market size and forecast, by Test Type
  - 7.6.5.3.2. Market size and forecast, by Disease Indication
  - 7.6.5.3.3. Market size and forecast, by End User
  - 7.6.5.4. Rest Of Mea
  - 7.6.5.4.1. Market size and forecast, by Test Type
  - 7.6.5.4.2. Market size and forecast, by Disease Indication
  - 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Quest Diagnostics
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Laboratory Corporation of America Holdings
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. F. Hoffmann-La Roche Ltd.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. ARUP Laboratories
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Walk-In Lab, LLC.
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. Applied InGENuity Diagnostics
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Scion Lab Services, LLC
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Baptist Health
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. My Care Labs
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Blueprint Genetics
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments

Product Code: A269963

LIST OF TABLES

TABLE 01. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 02. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR PROTEINS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR ELECTROLYTES, BY REGION, 2022-2032 ($MILLION)
TABLE 04. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY TESTS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER TESTS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 08. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 09. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 10. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIABTES, BY REGION, 2022-2032 ($MILLION)
TABLE 11. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 13. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 14. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2032 ($MILLION)
TABLE 15. COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 16. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 21. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 22. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 23. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 24. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 25. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 26. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 27. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 28. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 29. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 30. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 31. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 32. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 33. EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 34. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 35. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 36. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 37. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 38. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 39. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 40. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 41. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 42. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 43. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 44. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 45. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 46. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 47. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 48. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 50. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 51. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 54. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 55. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 56. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 57. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 58. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 59. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 60. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 61. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 62. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 63. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 64. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 66. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 67. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 69. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 70. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 74. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 75. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 76. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 77. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 78. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 79. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 80. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 81. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 82. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 83. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 84. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 85. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 86. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 87. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 88. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 89. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 90. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 91. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 92. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 93. MIDDLE EAST AND AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 94. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 95. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 96. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 97. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 98. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 99. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 100. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 101. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 102. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 103. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 104. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 105. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 106. QUEST DIAGNOSTICS: KEY EXECUTIVES
TABLE 107. QUEST DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 108. QUEST DIAGNOSTICS: PRODUCT SEGMENTS
TABLE 109. QUEST DIAGNOSTICS: SERVICE SEGMENTS
TABLE 110. QUEST DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 111. QUEST DIAGNOSTICS: KEY STRATERGIES
TABLE 112. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY EXECUTIVES
TABLE 113. LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
TABLE 114. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT SEGMENTS
TABLE 115. LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICE SEGMENTS
TABLE 116. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
TABLE 117. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES
TABLE 118. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 119. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 120. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 121. F. HOFFMANN-LA ROCHE LTD.: SERVICE SEGMENTS
TABLE 122. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 123. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 124. ARUP LABORATORIES: KEY EXECUTIVES
TABLE 125. ARUP LABORATORIES: COMPANY SNAPSHOT
TABLE 126. ARUP LABORATORIES: PRODUCT SEGMENTS
TABLE 127. ARUP LABORATORIES: SERVICE SEGMENTS
TABLE 128. ARUP LABORATORIES: PRODUCT PORTFOLIO
TABLE 129. ARUP LABORATORIES: KEY STRATERGIES
TABLE 130. WALK-IN LAB, LLC.: KEY EXECUTIVES
TABLE 131. WALK-IN LAB, LLC.: COMPANY SNAPSHOT
TABLE 132. WALK-IN LAB, LLC.: PRODUCT SEGMENTS
TABLE 133. WALK-IN LAB, LLC.: SERVICE SEGMENTS
TABLE 134. WALK-IN LAB, LLC.: PRODUCT PORTFOLIO
TABLE 135. WALK-IN LAB, LLC.: KEY STRATERGIES
TABLE 136. APPLIED INGENUITY DIAGNOSTICS: KEY EXECUTIVES
TABLE 137. APPLIED INGENUITY DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 138. APPLIED INGENUITY DIAGNOSTICS: PRODUCT SEGMENTS
TABLE 139. APPLIED INGENUITY DIAGNOSTICS: SERVICE SEGMENTS
TABLE 140. APPLIED INGENUITY DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 141. APPLIED INGENUITY DIAGNOSTICS: KEY STRATERGIES
TABLE 142. SCION LAB SERVICES, LLC: KEY EXECUTIVES
TABLE 143. SCION LAB SERVICES, LLC: COMPANY SNAPSHOT
TABLE 144. SCION LAB SERVICES, LLC: PRODUCT SEGMENTS
TABLE 145. SCION LAB SERVICES, LLC: SERVICE SEGMENTS
TABLE 146. SCION LAB SERVICES, LLC: PRODUCT PORTFOLIO
TABLE 147. SCION LAB SERVICES, LLC: KEY STRATERGIES
TABLE 148. BAPTIST HEALTH: KEY EXECUTIVES
TABLE 149. BAPTIST HEALTH: COMPANY SNAPSHOT
TABLE 150. BAPTIST HEALTH: PRODUCT SEGMENTS
TABLE 151. BAPTIST HEALTH: SERVICE SEGMENTS
TABLE 152. BAPTIST HEALTH: PRODUCT PORTFOLIO
TABLE 153. BAPTIST HEALTH: KEY STRATERGIES
TABLE 154. MY CARE LABS: KEY EXECUTIVES
TABLE 155. MY CARE LABS: COMPANY SNAPSHOT
TABLE 156. MY CARE LABS: PRODUCT SEGMENTS
TABLE 157. MY CARE LABS: SERVICE SEGMENTS
TABLE 158. MY CARE LABS: PRODUCT PORTFOLIO
TABLE 159. MY CARE LABS: KEY STRATERGIES
TABLE 160. BLUEPRINT GENETICS: KEY EXECUTIVES
TABLE 161. BLUEPRINT GENETICS: COMPANY SNAPSHOT
TABLE 162. BLUEPRINT GENETICS: PRODUCT SEGMENTS
TABLE 163. BLUEPRINT GENETICS: SERVICE SEGMENTS
TABLE 164. BLUEPRINT GENETICS: PRODUCT PORTFOLIO
TABLE 165. BLUEPRINT GENETICS: KEY STRATERGIES

LIST OF FIGURES

FIGURE 01. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN COMPREHENSIVE METABOLIC PANEL TESTING MARKET
FIGURE 04. TOP INVESTMENT POCKETS IN COMPREHENSIVE METABOLIC PANEL TESTING MARKET (2023-2032)
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. THREAT OF SUBSTITUTION
FIGURE 09. COMPETITIVE RIVALRY
FIGURE 10. GLOBAL COMPREHENSIVE METABOLIC PANEL TESTING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR PROTEINS, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR ELECTROLYTES, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY TESTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER TESTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION, 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR KIDNEY DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR LIVER DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIABTES, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER, 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF COMPREHENSIVE METABOLIC PANEL TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 26. COMPREHENSIVE METABOLIC PANEL TESTING MARKET BY REGION, 2022 AND 2032(%)
FIGURE 27. U.S. COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 28. CANADA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 29. MEXICO COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 30. GERMANY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 31. FRANCE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 32. UK COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 33. ITALY COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 34. SPAIN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 35. REST OF EUROPE COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 36. JAPAN COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 37. CHINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 38. INDIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 39. AUSTRALIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 40. SOUTH KOREA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 41. REST OF ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 42. BRAZIL COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 43. COLOMBIA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 44. ARGENTINA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 45. REST OF LA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 46. GCC COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 47. SOUTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 48. NORTH AFRICA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 49. REST OF MEA COMPREHENSIVE METABOLIC PANEL TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 50. TOP WINNING STRATEGIES, BY YEAR
FIGURE 51. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 52. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 53. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 54. COMPETITIVE DASHBOARD
FIGURE 55. COMPETITIVE HEATMAP: COMPREHENSIVE METABOLIC PANEL TESTING MARKET
FIGURE 56. TOP PLAYER POSITIONING, 2022

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ